[Study of the molecular and cellular mechanisms of action of lipid immunomodulators].
Within a narrow range of low concentrations (0.03-0.12 microgram/ml) polysialogangliosides containing unsaturated fatty acids in the lipid moiety of the molecule activate in vitro the proliferation of lymphocytes, synthesis of interleukin 2 and generation of highly active natural killers which are capable (in a [51Cr] test) of killing syngeneic, allogenic and xenogeneic tumor cells growing in vitro or maintained in mice (YAC-1, K562, Mch-11, SA-1, P-815, EL-4, Ehrlich carcinoma cells). We have developed biomethodology which allows one to introduce adequate concentrations of potent polysialogangliosides and phospholipids into specific macro- and microcompartments of immune system using two essentially different carriers. In experiments on mice this procedure leads to irreversible regression of subcutaneous nodules of syngeneic leukemias and sarcomas (EL-4, YAC, SA-1, Mchs-11) and of Ehrlich carcinoma with an initial size up to 1 cm, as well as to regression or prolonged inhibition of syngeneic cancers (Lewis and AMS-1) with nodules sizes up to 4-5 mm. Added cyclophosphamide increases this effect.
D000276:Adjuvants, Immunologic; D000818:Animals; D003602:Cytotoxicity, Immunologic; D005732:Gangliosides / Q000276:immunology / Q000627:therapeutic use; D006028:Glycosphingolipids / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007113:Immunity, Innate; D007694:Killer Cells, Natural / Q000276:immunology; D008055:Lipids / Q000276:immunology* / Q000627:therapeutic use; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D008815:Mice, Inbred Strains; D008934:Mitogens; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000628:therapy
D000276:Adjuvants, Immunologic; D005732:Gangliosides; D006028:Glycosphingolipids; D008055:Lipids; D008934:Mitogens
Issledovanie molekuliarnogo i kletochnogo mekhanizmov deĭstviia lipidnykh immunomoduliatorov.